Search
Cancer Types
Recurrent Ovarian Cancer
Clinical Trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
… MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS I Zsiros, Emese This is an open-label, phase 1, dose escalation …
Clinical Trial
A Phase 1, First-in-Human, Open-Label, DoseEscalation and Expansion Study of IMGN151 (anti-FR-alpha antibody drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers
… in Adult Patients with Recurrent Gynaecological Cancers I Zsiros, Emese IIMGN151-1001 is a Phase 1, first in human, …
Clinical Trial
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer
… CDX-1140 in Patients with Recurrent Ovarian Cancer II Zsiros, Emese This phase II trial tests whether pembrolizumab …
Clinical Trial
NRG-GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
… Low-Grade Serous Carcinoma of the Ovary or Peritoneum III Zsiros, Emese This phase III trial studies how well letrozole …
Clinical Trial
Randomized Phase 2 Trial of APL-2 with Pembrolizumab vs. APL-2 with Pembrolizumab and Bevacizumab vs. Bevacizumab alone in Patients with Recurrent Ovarian Cancer and Persistent Malignant Effusion
… Ovarian Cancer and Persistent Malignant Effusion II Zsiros, Emese This phase II trial studies the effect of APL-2 …
Clinical Trial
A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer ( 27T51-01)
… primary peritoneal, or fallopian tube cancer ( 27T51-01) I Zsiros, Emese This study is researching an experimental CAR T …
Cancer Types
Why Roswell Park for Ovarian Cancer
… than follow NCCN guidelines; they help write them. Emese Zsiros, MD, PhD, FACOG , Chair of Gynecologic Oncology, sits … than follow NCCN guidelines; they help write them. Emese Zsiros, MD, PhD, FACOG , Chair of Gynecologic Oncology, sits …